亦诺微完成1.02亿人民币A+轮融资 鸣笛起航原创溶瘤产品临床研究 | 新闻稿
Immvira Announces US$15 Million Series A+ Fundraising to Advance oHSV Clinical Studies
January 31, 2019/ Immvira has announced today that it has closed its Round A+ fundraising of $15 million U.S. dollars. The lead investor is a premium global investment firm, together with Mefund Capital, Leaguer Group Co., Ltd, Bohe Angel, and with additional investment from investors in previous funding round (Round A), including Taifu Capital, Triwise Capital and Yonghua Capital. This investment will be used to initiate clinical study of current product T3 which is a single therapeutic agent of three distinct cancer therapies: the targeting of cancer cells by oncolytic viruses, the stimulation of immune system by IL12, and the production of immunotherapeutic antibodies against PD-1. This investment will also be used to extend oHSV pipelines and platforms as well.
Immvira was founded in Shenzhen China in May of 2015 by Prof. Bernard Roizman of the University of Chicago. Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of the University of Alabama, and Prof. Ralph Weichselbaum of the University of Chicago. Immvira closed its Round A fundraising of 50 Million RMB in September 2016 to develop independently the first two products T2 and T3, which to be conduct clinical trials in US, Australia and China soon.
Professor Bernard Roizman, the founder and chairman of Immvira said, “We are very honored to receive the support of top bio-pharmaceutical investment institutions, reflecting the recognition to our scientific background, product pipeline, development strategy and business model as well. It will greatly facilitate the process of clinical research of Immvira products."
"The successful completion of this round of financing, especially in the cool capital market, has added a fire to Immvira." Dr. Grace Zhou the founder and CEO of Immvira said, “We will continually maintain rigorous scientific attitude, secure our future by creating a company of inspiring people, building innovative pipelines and conducting productive clinical studies.